Diabetes;Diabete

Medecine et Hygiene

Volumn 55, Issue 2145, 1997, Pages

  Gerber, P ^a  

^a Clinica Al Parco   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLIMEPIRIDE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; TROGLYTAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET; GLUCOSE INTOLERANCE; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY;

EID: 0031016635     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (27)

1. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study IV. Characteristics of newly presenting type 2 diabetic patients: Male preponderance and obesity at differents ages: Multicentre study. Diabetic Med 1988; 5: 154-9.
2. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study VII. Response of fasting plasma glucose to diet therapy in newly presenting II diabetic patients. Metabolism 1990; 39: 905-12.
3. UK Prospective Diabetes Study Group: UKPDS VIII. Study design progress and performance. Diabetologia 1991; 34: 877-90.
4. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study (UKPDS) XI. Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabetic Med 1994; 11: 534-44.
5. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study (UKPDS) XII. Differences between Asian, Afro-Caribbean and White Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabetic Med 1994; 11: 670-7.
6. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 1995; 310: 83-8.
7. Turner RC, Holman RR. Lessons from UK Prospective Diabetes Study, Diabetes Research and Clinical Practice 1995; (Suppl. 28): 151-57.
8. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
9. Turner R, Cull C, Holman R, for the United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Sudy 17. A 9-Year Update of a Randomized, Controlled Trial on the effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus. Ann Intern Med 1996; 124:136-45.
10. Eeley EA, Stratton IM, Hadden DR, Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group. UKPDS 18: Estimated Dietary take in Type 2 Diabetic Patients Randomly Allocated to Diet, Sulphonylurea or Insulin Therapy. Diabetic Med 1996; 13: 656-62.
11. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347: 949-50.
12. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu heart program. Diabetes 1987; 36: 689-92.
13. Burchfiel CM, Curb ID, Rodriguez BL, Abbott RD, Chin D, Yano K. Glucose intolerance and 22-year stroke incidence: The Honolulu heart program. Stroke 1994; 25: 951-7.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in the insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
15. Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular event and riskfaclors in the diabetes control and complications trial. Am J Cardiol 1995; 75: 894-903.
16. Malberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (Digami study): Effects on mortality at I year. J Am Coll Cardiol 1995; 26: 57-65.
17. Keen H. Jarrett RJ, McCanney P. The ten-year follow up of the Bedford survey (1962-72): Glucose tolerance and diabetes. Diabetologia 1982; 22: 73-8.
18. Bloomgarden ZT, Conference Report. Approaches to the Treatment of Type II Diabetes and Developments in Glucose Monitoring and Insulin Administration. Diabetes Care 1996; 19: 906-9.
19. David MJ, Grant IP. Impaired glucose tolerance: Detection and follow up should aim to reduce excess morbidity and mortality. BMJ 1996; 312: 264-5.
20. University Group Diabetes Program. A study of the effects of hypoglicemic agents on vascular complications in patients with adult-onest diabetes V. Evalutation of phenformin therapy. Diabetes 1975; 24 (Suppl. 1): 65-184.
21. Meinert CL Knatterud CL, Prout TE, Klimt CT. A study of the effects of hypoglicemic agents on vascular complications in patients with adult-onset diabetes II. Mortality results. Diabetes 1970; (Suppl. 2) 19: 789-830.
22. Kumar S. Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P, for the Troglitazone study group. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-9.
23. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone. Diabetic Med 1996; 13: 365-70.
24. Bloomgarden ZT. New and Traditional Treatment of Glycemia in NIDDM. Diabetes Care 1996; 19: 295-9.
25. Draeger KE, Wernicke-Panten K, Lamp HJ, Schüler S, Rosskamp R. Glimepiride Multicentre Study Group, Clinical Research, Hoeschst AG. Frankfurt, Germany. Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent glimepiride (Amaryl®): A Double-Blind Comparison with glibenclamide. Harm Metab Res 1996; 28: 419-25.
26. Keen H. Non-insulin dependent diabetes needs more attention. BMJ 1996; 313: 510.
27. Van der Does FEE, Nico J, De Neeling JND, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM, Heine RJ. Symptoms and Well - Being in Relation to Glycemic Control in Type II Diabetes. Diabetes Care 1996; 19: 204-10.